Form 4: Seres Therapeutics CEO Eric Shaff Awarded Stock Options
SEC Form 4 Filing
Seres Therapeutics CEO Eric D. Shaff was granted stock options for 1,950,000 shares on February 7, 2025, according to a Form 4 filing.
Summary
- Eric D. Shaff, CEO and President of Seres Therapeutics, Inc., was granted stock options on February 7, 2025.
- The options are for 1,950,000 shares of Seres Therapeutics common stock.
- The exercise price of the options is $0.782 per share.
- The options vest as to 25% of the shares on February 7, 2026, and the remainder vest in 12 equal quarterly installments thereafter.
- The options expire on February 6, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the CEO's ability to drive future growth. The vesting schedule promotes long-term alignment.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term performance.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance, only details of the vesting schedule of the options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The size of the grant and the vesting schedule are typical for a CEO of a company of Seres Therapeutics' size and stage of development.
- Comparable companies such as Synlogic, Finch Therapeutics, and Vedanta Biosciences also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders: The stock option grant aligns the CEO's interests with those of shareholders, incentivizing him to increase shareholder value.
- Employees: The grant could boost employee morale by demonstrating confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 02/07/2025 | Date of the stock option grant. |
| 02/07/2026 | Date when 25% of the stock options vest. |
| 02/06/2035 | Expiration date of the stock options. |
| 02/11/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.